Gaudium IVF IPO GMP

February 24, 2026 Written By Mihir Gohel, Reviewed and Fact Checked by Harpal Parmar

Gaudium IVF IPO opens for subscription on February 20, 2026, and closes on February 24, 2026, with an issue size of ₹165 crore comprising ₹90 crore fresh issue and ₹75 crore offer for sale priced at ₹75 – ₹79 per share for listing on BSE and NSE on February 27. Delhi-based Gaudium IVF IPO operates 12 centers across North India specializing in fertility treatments and women healthcare, delivering 4,000+ IVF cycles annually with 45% success rates led by Dr. Manika Khanna. Founded in 2009, the chain emphasizes advanced ART protocols and integrated gynecology services targeting urban infertility rise.

₹00

Latest IPO GMP

Last updated on 26 Feb 2026 19.45

₹79

IPO Offer Price

*cut off price

₹

Listing Price

Listing Date 27/02/2026

Expert Opinions

Market sentiment for Gaudium IVF IPO demonstrates healthcare sector enthusiasm, supported by strong clinical reputation and demographic infertility trends despite competitive landscape concerns. Company strengths comprise proprietary GAAT protocols delivering 58.74% success rates surpassing industry benchmarks, integrated pharmacy revenue stabilizing 40.8% EBITDA margins, 47.6% cycle volume growth across 12 centers, and founder-led clinical excellence.

Risks involve specialist doctor retention critical for outcomes, regulatory scrutiny on ART pricing, geographic concentration limiting scale, and high capex intensity for new facilities. Valuation analysis for Gaudium IVF IPO and year 2025 exhibits Return on Equity (ROE) of 41.31%, ROCE of 39.70%, and Net Asset Value (NAV) of ₹7.54, positioned at attractive 7.8x EV/EBITDA versus peers trading 15x+. Long-term investment perspective capitalizes on 13% IVF market expansion through Tier-II urbanization and medical tourism acceleration.

Investor Considerations

Gaudium IVF IPO exhibits strong company performance and fundamentals in FY 2025, achieving revenue growth of 47.6% to ₹70.72 crore and PAT of ₹19.13 crore with 40.8% EBITDA margins from expanded ART cycles and pharmacy revenues. IVF sector outlook projects 13% CAGR to ₹20,000 crore by 2030 driven by rising infertility prevalence, medical tourism, and Tier-II penetration. IPO Valuation of Financial Year 2025 for Gaudium IVF IPO and year displays Price to Book Value of 10.48, PAT Margin of 26.96%, and Debt/Equity of 0.41, commanding premium on superior clinical outcomes.

Growth prospects include 10 new centers rollout and protocol innovations targeting 20% cycle volume increase annually. Risk factors feature physician dependency, regulatory approvals for expansions, regional concentration, and treatment success variability. Short-term investment goals navigate healthcare volatility, while long-term horizons capitalize on demographic infertility compounding.